ASH 2024
In oncology and hematology, success hinges on designing and executing trials that truly make a difference—from the start. At Syneos Health, we combine clinical innovation with deep therapeutic expertise to accelerate the success of your trial. As the go-to partner for clinical trials, including gene therapy, in both malignant and classical hematological conditions, we’ve supported over 600 oncology/hematology studies since 2019.
We also offer unparalleled commercial expertise. Whether it's leveraging real-world evidence, simplifying complex narratives for stakeholder engagement, or filling in the gaps in your commercial engagement solutions, we help turn your innovations into market-leading therapies that improve patient outcomes.
Meet with us at ASH 2024 to explore how Syneos Health can help you implement innovative adaptive trial designs and leverage cutting-edge biostatistical methods to optimize trial outcomes.
Poster Presentation
Usage of Disease-Specific Patient Reported Outcome Measures (PROMs) for Assessing Quality of Life (QoL) in Industry Sponsored Hemophilia Interventional Trials
Senior Medical Director, Oncology & Hematology
Other Attendees
Wael Harb, MD, Vice President Medical Management
Patrick Melvin, Vice President of Therapeutic Strategy and Innovation, Oncology
Patrick Kelley, MD, Vice President, Medical Management
Susan Cooper, Vice President, West Coast Biotech Specialist
Scott Fitzsimmons, Head of Oncology
Paula Bain, President, Clinical Development
Stephanie Gonzalez, Managing Director, Operations
John Grant, Executive Director, Commercial
Todd Ungard, Vice President, Commercial
Related Content
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
End-to-End Expertise in Early-Phase Oncology
Oncology Expertise at all Levels
Expertise in Nonmalignant Hematology
